Bank of America Global Research upped its rating on Regeneron Pharmaceuticals and its price target to $860 because it has a better view on Eylea HD, Dupixent is growing steadily, and there are several catalysts for 2026. Bank of America Global Research raised its rating on Regeneron …
Read More
About The Author
